Phase I trial of single-agent recombinant human anti-vascular endothelial growth factor (GB222) followed a combination therapy of GB222 and temozolomide in patients with recurrent WHO grade III and IV glioma
xun kang, Wenbin Ma, Weiping Li, S. Qi, Chongyuan Xu, Xuejun Yang, Liming Wang, Chao Gao, F. Chen, Ce Wang, Z. Kang, Chuanlu Jiang, Wenbin Li
{"title":"Phase I trial of single-agent recombinant human anti-vascular endothelial growth factor (GB222) followed a combination therapy of GB222 and temozolomide in patients with recurrent WHO grade III and IV glioma","authors":"xun kang, Wenbin Ma, Weiping Li, S. Qi, Chongyuan Xu, Xuejun Yang, Liming Wang, Chao Gao, F. Chen, Ce Wang, Z. Kang, Chuanlu Jiang, Wenbin Li","doi":"10.1007/s44194-022-00010-1","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":72735,"journal":{"name":"Current medicine (Cham, Switzerland)","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current medicine (Cham, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s44194-022-00010-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
